消息

Text body: Verrica Pharmaceuticals Inc. (VRCA) announced the dosing of the first U.S. patient in its global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. The COVE-3 study will enroll patients in both the U.S. and Japan, while the COVE-2 study is enrolling only U.S. patients. Torii Pharmaceutical, Verrica's Japanese d...

全文

The positive data may also support a narrower toxicology package and a faster development timeline, allowing Solvonis to move more efficiently towards an IND application for its planned Phase 2b trial. The next steps include discussions with the FDA on toxicology requirements.

全文

The company is repurposing Johnson & Johnson's approved esketamine treatment Spravato, aiming to tap into a substantial commercial opportunity in alcohol use disorder, which affects approximately 15 million American adults. Tennyson highlighted that this market is significantly larger than the current indication for treatment-resistant depression....

全文

Solvonis Therapeutics (LSE:SVNS) has made significant progress in advancing its SVN-002 programme for moderate to severe alcohol use disorder. CEO Anthony Tennyson announced positive bridging pharmacokinetic data, demonstrating that esketamine delivered sublingually or bucally provides comparable exposure levels as intranasal administration. This i...

全文

MoonLake Immunotherapeutics (MLTX) announced strong one-year results from two Phase 3 trials of its experimental drug sonelokimab in patients with hidradenitis suppurativa. The company reported that approximately two-thirds of treated patients achieved a high level of disease improvement after 52 weeks, while about one-third experienced complete cl...

全文

Erasca, Inc.'s common stock has been the subject of a class action lawsuit filed on behalf of investors who purchased shares between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca made false and misleading statements about its lead oncology drug candidate, ERAS-0015, during this period. Specifically, it is claimed that the c...

全文

KeyCorp’s stock has delivered a 45.7 % total shareholder return over the past year, with a 30‑day return of 5.12 % and a 90‑day return of 16.38 %. Risks highlighted include potential rises in non‑performing loans, higher capital requirements that could limit cash distributions, and the possibility of higher operating expenses dampening the project...

全文

Market consensus places KeyCorp’s fair value near US$25.03 per share, with a price target of US$25.06 and an intrinsic discount of about 39 %. The Excess Returns model values the stock at US$37.30, implying a 39.4 % undervaluation relative to the current price of US$22.59. A price‑to‑earnings ratio of 13.53× places the bank above the industry ave...

全文

The company’s financial outlook projects revenue of US$9.3 billion and earnings of US$2.5 billion by 2029, a 9 % annual growth requirement. Some analysts project even stronger performance, with revenue rising 14 % per year and earnings around US$2.3 billion. The investment in technology could boost margins and fee income, but also raises the risk...

全文

KeyCorp recently launched fixed‑income notes due 2031, signalling a shift toward a more balanced debt‑to‑equity financing mix. The notes provide capital for a planned US$1 billion technology and AI investment program that is expected to drive operational efficiency and help the bank transition from net interest income (NII) headwinds to tailwinds....

全文